Augtyro ‘Fills a Gap’ in the Treatment of ROS1-Positive NSCLC
December 4th 2023The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.
Read More